Regencell Bioscience Ltd (RGC) - Market Cap to Net Income Ratio
The absence of market barriers and early-stage testing create risks, however, Regencell Bioscience (RGC) will see profit growth through the sale of natural remedies for ADHD and autism. The company's average P/E reflects valuation payback dynamics, where the current level is -237.80. The strategy is based on implementing traditional Chinese medicine as an eco-friendly alternative to synthetic drugs for patients with neurodevelopmental disorders.
Comprehensive metric breakdowns and analytics for Regencell (RGC)
- market price and analyst price targets:
- market capitalization indicators:
- shareholders' equity book value data:
- debt and solvency information:
Total Debt to Equity Ratio Regencell Bioscience|RGC - Long-Term Debt to Capital|Current Liabilities to Capital Regencell Corp|RGC - Company Debts|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited|RGC - Company Long-Term Debt|Company Short-Term Debt Regencell Bioscience|Intermediate Coverage Ratio regencellbioscience.com
- business earnings and investment ratios data:
RGC - Net Profit|Expected Profit Regencell Bioscience|RGC - P/E Multiple|Market Cap to Projected Earnings Regencell Bioscience Ltd|RGC - Price/Earnings to Growth Ratio|Company Value to EBITDA Regencell Bioscience Holdings Limited|RGC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Regencell Bioscience|RGC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months regencellbioscience.com|RGC - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Regencell Bioscience
Comprehensive company analysis:regencellbioscience.com
The P/E ratio reflects the market value of one unit of net profit, allowing an investor to determine the degree of overpayment for an asset by comparing quotes with the business's actual earnings. When analyzing the P/E ratio of Regencell Bioscience (RGC), one should consider the commercialization potential of drugs for treating neurological disorders, as future payouts from Asian insurance funds may justify the current fundamental value of the business.
Analysis of competing companies
Market Cap to Earnings biogen.com BIIB|P/E Multiple NBIX|Axsome (AXSM) - Market Cap to Net Income Ratio|P/E Multiple ACAD (ACADIA Pharmaceuticals Inc)|Xenon Corp (XENE) - Market Cap to Earnings|VKTX - Price to Earnings Ratio|SUPN (supernus.com) - Price to Earnings Multiple|CPRX: P/E Multiple|Price to Earnings Ratio Denali|HRMY (Harmony Pharma) - P/E Multiple|Market Cap to Earnings Biohaven Corp BHVN|Price to Earnings Ratio Amylyx Pharmaceuticals (AMLX)|Price to Earnings Ratio TRVI (trevitherapeutics.com)|Price to Earnings Ratio Praxis Precision Medicines, Inc. PRAX|Anavex - Price to Earnings Ratio|CBLL: Price to Earnings Ratio|Company Value to Net Income PRTA (Prothena Corporation)|ALEC: P/E Multiple|ANNX (annexonbio.com) - Price to Earnings Ratio|OMER (Omeros Corp) - P/E Multiple|Neurogene Inc (NGNE) - Business Payback Period|Price to Earnings Ratio AC Immune Corp (ACIU)|VYGR - Market Cap to Earnings|Price to Earnings Ratio Neumora Therapeutics NMRA|Business Payback Period scilexholding.com (SCLX)|Tevogen Bio - P/E Multiple|Alpha Cognition (ACOG) - Price to Earnings Ratio|CGTX: P/E Multiple|IKT - Business Payback Period|SAVA (Cassava Sciences, Inc.) - P/E Multiple|Market Cap to Earnings Assertio Therapeutics ASRT|Price to Earnings Ratio Coya Therapeutics, Inc. (COYA)|vistagen.com - Price to Earnings Multiple|P/E Multiple OVID (Ovid Therapeutics)|ABOS - Price to Earnings Ratio|CervoMed Inc. - P/E Multiple|Market Cap to Earnings Alterity Therapeutics|clene.com (CLNN) - Price to Earnings Ratio|PepGen - Company Value to Net Income|JUNS (Jupiter Neurosciences) - P/E Multiple|RLMD - Market Cap to Net Income Ratio|P/E Multiple ANVS|Price to Earnings Ratio gracetx.com GRCE|Price to Earnings Ratio Firefly Neuroscience AIFF|KLTO: Price to Earnings Multiple|NeuroSense Therapeutics, Ltd. - P/E Multiple|Market Cap to Earnings Reviva Pharmaceuticals, Inc.|MTVA (metaviatx.com) - Price to Earnings Ratio|neuraxis.com (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical Technologies, Inc.|PASG: Company Value to Net Income|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|NERV - Market Cap to Earnings|Price to Earnings Ratio Athira Pharma, Inc. ATHA|Company Value to Net Income ADXN|Alzamend - P/E Multiple|Market Cap to Earnings Cyclerion Therapeutics|PTIX: P/E Multiple|Market Cap to Net Income Ratio Pasithea Therapeutics Corp. KTTA|CRGT (Cortigent Inc) - P/E Multiple|Market Cap to Earnings avenuetx.com ATXI|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|Cara Therapeutics Inc. - Price to Earnings Multiple|P/E Multiple CHRO (Chromocell Therapeutics Corporation)|ELYM - Price to Earnings Ratio|Intra-Cellular - P/E Multiple|Market Cap to Earnings longboardpharma.com|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|NKGN (NKGen Biotech Inc) - Price to Earnings Ratio|Price to Earnings Ratio NeuroBo|Price to Earnings Ratio SAGE|Price to Earnings Ratio SNPX (Synaptogenix, Inc.)|TRVN (trevena.com) - Company Value to Net Income|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|anewmeds.com - Price to Earnings Ratio|Cerevel - P/E Multiple
